7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Yamashita T et al. | Retardation in bone resorption after bone marrow ablation in klotho mutant mice. | 2000 | Endocrinology | pmid:10614667 |
Hofbauer LC et al. | The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | 2000 | J. Bone Miner. Res. | pmid:10646108 |
Kanzawa M et al. | Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. | 2000 | Eur. J. Endocrinol. | pmid:10822231 |
Mukohyama H et al. | The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10777696 |
Atkins GJ et al. | Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. | 2000 | J. Bone Miner. Res. | pmid:10780856 |
Thompson SW and Tonge D | Bone cancer gain without the pain. | 2000 | Nat. Med. | pmid:10802700 |
Honore P et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | 2000 | Nat. Med. | pmid:10802707 |
Onyia JE et al. | In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. | 2000 | J. Bone Miner. Res. | pmid:10804015 |
Bateman TA et al. | Osteoprotegerin mitigates tail suspension-induced osteopenia. | 2000 | Bone | pmid:10773583 |
Malyankar UM et al. | Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. | 2000 | J. Biol. Chem. | pmid:10811631 |
Thirunavukkarasu K et al. | The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. | 2000 | J. Biol. Chem. | pmid:10833509 |
Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Medscape Womens Health | pmid:10792853 |
Fata JE et al. | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. | 2000 | Cell | pmid:11051546 |
Miyamoto N et al. | Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. | 2000 | J. Orthop. Res. | pmid:11052502 |
Kinpara K et al. | Osteoclast differentiation factor in human osteosarcoma cell line. | 2000 | J Immunoassay | pmid:11071251 |
Kong YY et al. | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | 2000 | Immunol. Today | pmid:11071528 |
Kobayashi Y et al. | Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. | 2000 | J. Bone Miner. Res. | pmid:11028444 |
Miyamoto T et al. | An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. | 2000 | Blood | pmid:11110710 |
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | Bone | pmid:11113385 | |
Takayanagi H et al. | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. | 2000 | Nature | pmid:11117749 |
Mancini L et al. | Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. | 2000 | Biochem. Biophys. Res. Commun. | pmid:11118297 |
Lee ZH et al. | Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. | 2000 | Mol. Pharmacol. | pmid:11093794 |
Kong YY and Penninger JM | Molecular control of bone remodeling and osteoporosis. | 2000 | Exp. Gerontol. | pmid:11121682 |
Shalhoub V et al. | Characterization of osteoclast precursors in human blood. | 2000 | Br. J. Haematol. | pmid:11122091 |
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | J. Bone Miner. Res. | pmid:11127193 | |
Sakuma Y et al. | Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. | 2000 | Infect. Immun. | pmid:11083800 |
Riggs BL | The mechanisms of estrogen regulation of bone resorption. | 2000 | J. Clin. Invest. | pmid:11086020 |
Udagawa N et al. | Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. | 2000 | Endocrinology | pmid:10965921 |
Yasuda H | [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. | 2000 | Seikagaku | pmid:10967683 |
Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
Lacey DL et al. | Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. | 2000 | Am. J. Pathol. | pmid:10934148 |
Quinn JM et al. | Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. | 2000 | J. Bone Miner. Res. | pmid:10934644 |
Min H et al. | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. | 2000 | J. Exp. Med. | pmid:10952716 |
Shiba H et al. | Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. | 2000 | Mech. Ageing Dev. | pmid:10958924 |
López FJ | New approaches to the treatment of osteoporosis. | 2000 | Curr Opin Chem Biol | pmid:10959765 |
Nakashima T et al. | Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10973797 |
Itoh K et al. | Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. | 2000 | J. Bone Miner. Res. | pmid:10976996 |
Schinke T and Karsenty G | Vascular calcification--a passive process in need of inhibitors. | 2000 | Nephrol. Dial. Transplant. | pmid:10978374 |
Lorenzo J | Interactions between immune and bone cells: new insights with many remaining questions. | 2000 | J. Clin. Invest. | pmid:10995785 |
Teng YT et al. | Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. | 2000 | J. Clin. Invest. | pmid:10995794 |
Børset M et al. | Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. | 2000 | Blood | pmid:11001907 |
Hofbauer LC and Heufelder AE | Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. | 2000 | J. Clin. Endocrinol. Metab. | pmid:10902778 |
Rani CS and MacDougall M | Dental cells express factors that regulate bone resorption. | 2000 | Mol. Cell Biol. Res. Commun. | pmid:10860862 |
Tsurukai T et al. | Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. | 2000 | J. Bone Miner. Metab. | pmid:10874596 |
Günther T and Schinke T | Mouse genetics have uncovered new paradigms in bone biology. | 2000 | Trends Endocrinol. Metab. | pmid:10856921 |
Capparelli C et al. | Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. | 2000 | Cancer Res. | pmid:10706080 |
Makhluf HA et al. | Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10679262 |
Merewether LA et al. | Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. | 2000 | Arch. Biochem. Biophys. | pmid:10683254 |
Ross FP | RANKing the importance of measles virus in Paget's disease. | 2000 | J. Clin. Invest. | pmid:10712423 |
Tricot G | New insights into role of microenvironment in multiple myeloma. | 2000 | Lancet | pmid:10675068 |
Takayanagi H et al. | Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. | 2000 | Arthritis Rheum. | pmid:10693864 |
Itonaga I et al. | Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. | 2000 | Ann. Rheum. Dis. | pmid:10627423 |
Chikatsu N et al. | Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10631114 |
Takami M et al. | Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. | 2000 | Endocrinology | pmid:11108286 |
Gori F et al. | The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. | 2000 | Endocrinology | pmid:11108292 |
Clohisy DR et al. | Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. | 2000 | J. Orthop. Res. | pmid:11192258 |
Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Osteoporos Int | pmid:11193242 |
Wise GE et al. | Osteoprotegerin and osteoclast differentiation factor in tooth eruption. | 2000 | J. Dent. Res. | pmid:11201042 |
Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
Saika M et al. | 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. | 2001 | Endocrinology | pmid:11356664 |
Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
Zhang YH et al. | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. | 2001 | J. Biol. Chem. | pmid:11032840 |
Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
Takemura M et al. | Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. | 2001 | Metab. Clin. Exp. | pmid:11172466 |
Gravallese EM et al. | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. | 2001 | Arthritis Res. | pmid:11178122 |
Makiishi-Shimobayashi C et al. | Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11181055 |
Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
Wan M et al. | Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. | 2001 | J. Biol. Chem. | pmid:11139569 |
Price PA et al. | Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11597934 |
Nemec K and Schubert-Zsilavecz M | [Future therapies for metabolic bone diseases. New concepts and targets]. | 2001 | Pharm Unserer Zeit | pmid:11715689 |
Kuntz KA et al. | An immunohistochemical study of osteoprotegerin in the human dental pulp. | 2001 | J Endod | pmid:11716077 |
Hofbauer LC and Schoppet M | Serum measurement of osteoprotegerin--clinical relevance and potential applications. | 2001 | Eur. J. Endocrinol. | pmid:11720890 |
Ueland T et al. | Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. | 2001 | Eur. J. Endocrinol. | pmid:11720891 |
Chikazu D et al. | Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. | 2001 | J. Bone Miner. Res. | pmid:11697804 |
Khosla S | Minireview: the OPG/RANKL/RANK system. | 2001 | Endocrinology | pmid:11713196 |
Seidel C et al. | Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. | 2001 | Blood | pmid:11568016 |
Fukagawa M et al. | Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. | 2001 | Am. J. Kidney Dis. | pmid:11576943 |
Sato T et al. | Osteoprotegerin levels before and after renal transplantation. | 2001 | Am. J. Kidney Dis. | pmid:11576949 |
Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
Sakai E et al. | Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. | 2001 | J. Biochem. | pmid:11726283 |
Haynes DR et al. | The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. | 2001 | J Bone Joint Surg Br | pmid:11521937 |
Hofbauer LC and Schoppet M | Osteoprotegerin: a link between osteoporosis and arterial calcification? | 2001 | Lancet | pmid:11498208 |
Sakai A et al. | 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. | 2001 | J. Bone Miner. Metab. | pmid:11498729 |
Ikeda T et al. | Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. | 2001 | J. Bone Miner. Res. | pmid:11499864 |
Thomas GP et al. | Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. | 2001 | J. Endocrinol. | pmid:11479141 |
Allan GF et al. | Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. | 2001 | Steroids | pmid:11546554 |
Feige U | Osteoprotegerin. | 2001 | Ann. Rheum. Dis. | pmid:11890662 |
Giuliani N et al. | Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. | 2001 | Blood | pmid:11739153 |
Croucher PI et al. | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. | 2001 | Blood | pmid:11739154 |
Dhore CR et al. | Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. | 2001 | Arterioscler. Thromb. Vasc. Biol. | pmid:11742876 |
Ramalho AC et al. | Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. | 2001 | Cytokine | pmid:11792122 |
Yano K et al. | Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. | 2001 | J. Bone Miner. Metab. | pmid:11685652 |
Kawahara N et al. | Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. | 2001 | Chem. Pharm. Bull. | pmid:11605678 |
Boissy P et al. | RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11606048 |
Wise GE et al. | Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. | 2001 | Clin Anat | pmid:11301468 |
Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |